I've been asked to present an overview of the application
of Evidence-Based-Medicine to Behavioral Therapies, in
particular biofeedback. Although I have a number of points
already in mind, I'd be interested if anyone can contribute
suggestions of other authors that have addressed this
particular topic.
One example of a problem area is the purity of the
therapeutic agent. In pharmaceutical research we have,
quite outside the experimental setting, the assurance of
the FDA and FDA-monitored manufacturer that the
experimental drug really is 10 mg of Ditropan (or whatever).
But there is no such agency monitoring the purity of
"biofeedback" treatments, so it may be that everyone
is getting the placebo!
Has anyone been thinking or writing along these lines?
John Perry
John D. Perry, PhD, MDiv, BCIA-C, Dip.ABS
1192 Lakeville Circle * Petaluma, CA 94954 USA
Phone: 707-789-9135 * FAX: 707-789-9137
Current Email: [log in to unmask]
Email Forwarder: [log in to unmask]
Website: http://www.InContiNet.com
|